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CONCLUSION: There were considerable differences in
the use of medical services by patients with schizophre-
nia. Of the four cohorts examined, clozapine users had
the fewest hospitalizations at baseline and during the fol-
low-up period, but also the highest costs.
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Following recommended dosage and duration protocols
from the start of a treatment episode is essential to
achieving optimal clinical outcomes through pharmaco-
therapy. For retrospective claims database analysis of an-
tipsychotic medications, early refills and/or dose titration
can complicate comparisons of an individual patient’s
dose and duration pattern to recommended protocols.
OBJECTIVE: The objective was to determine whether an
algorithm adjusting for early refills and dose titrations in
antipsychotic claims resulted in significant changes.
METHODS: Antipsychotic prescriptions dispensed be-
tween October 1995 and December 1997 to 21,536 eligi-
ble subjects were extracted from a large US prescription
claims database. Patients starting a new episode—initia-
tors (n  3244)—received their initial antipsychotic med-
ication between October 1996 and December 1996, but
received no antipsychotic agents in the preceding 365
days. Antipsychotics dispensed within 365 days after the
initial agent were used to calculate mean daily dose and
duration for initiators by medication. Paired t tests as-
sessed differences between patient-level dose and dura-
tion measures calculated with and without the algorithm.
RESULTS: Use of the algorithm significantly reduced du-
ration and significantly raised mean daily doses for initia-
tors taking one of seven antipsychotic medications. For
three agents—olanzapine, risperidone, and thioridazine—
both dose and duration differences were significant at p 	
0.0001. Dosing and duration p-values, respectively, for the
other agents were: chlorpromazine (0.0024, 0.0329), halo-
peridol (0.0017, 0.0002), perphenazine (0.0101, 0.0003),
and trifluoperazine (0.0348, 0.0026).
CONCLUSIONS: Applying the algorithm resulted in sig-
nificant changes to antipsychotic dose and duration val-
ues. Therefore, before comparing patterns developed
from retrospective antipsychotic claims to recommended
guidelines, dose and duration must be adjusted to ac-
count for early refills and/or titration.
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OBJECTIVES: To investigate whether the association be-
tween higher healthcare costs and delays or changes in an-
tipsychotic drug therapy, which was found in previous
1-year period study, continue to accrue over a 2-year
period.
METHODS: For this study 1966 patients with schizo-
phrenia covered by the California Medicaid (Medi-Cal)
program were selected. Multiple logistic regression mod-
els were estimated for the likelihood of delaying therapy
and changing therapy and OLS regressions were used to
estimate the cost effects of these drug use patterns in both
1-year and 2-year models.
RESULTS: Of patients, 21.1% did not use an antipsy-
chotic medication in the first year and 17.6% were un-
treated for 2 years. As before, treated patients used sig-
nificantly less psychiatric hospital services over 2 years
($6906, p  0.0025), but more nursing home services
($7508, p  0.0074) and prescription drugs ($962,
p  0.0001). Nearly 28% of patients treated within 2
years delayed the onset of drug therapy more than 30
days. Having started a delayed course of antipsychotic
therapy during the first year was associated with signifi-
cantly higher first year total costs ($5223, p  0.0270).
However, this impact of delayed therapy measured over
2 years decreased to $2678 (p  0.5158). For patients
with no delay in the start of drug therapy, 48% change
therapy in the first year, which increases to nearly 55%
after 2 years. Patients who change drug therapy exhibit
significantly higher costs: $10,517 after 1 year and
$15,206 over 2 years.
CONCLUSIONS: As in the earlier analysis, antipsychotic
drug use patterns in Medi-Cal suggest that standard med-
ications do not meet the therapeutic needs of patients
with schizophrenia, which results in higher total health-
care costs.
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OBJECTIVE: The purpose of this present study was to
ascertain the economic burden due to the annual direct
costs of psychotropic medications used in the manage-
ment of psychiatric disorders in a developing country
with limited financial resources.
METHODS: The direct costs of the psychopharmacologi-
cal agents evaluated were: 1) antidepressants like tricyclic,
SSRI, and newer antidepressants available; 2) antipsychot-
ics like phenothiazines, butyrophenones, and atypical an-
tipsychotics; 3) benzodiazepines and sedatives. The annual
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direct costs of the medications were ascertained from the
latest monthly index for medical specialities (MIMS), and
from standard chemists, and pharmaceutical firms. The
statistical mode or most frequent cost was considered for
further computations.
RESULTS: Regarding antidepressants, tricyclics were noted
to have the following annual direct costs (1 US $  Rs. 43):
Imipramine Rs. 1130 (US$26.3), amitriptyline Rs. 1460
($34), dothiepin Rs. 2410 ($56.1), trimipramine Rs. 2430
($56.5) and clomipramine Rs. 6130 ($142.6). Fluoxetine
has an annual cost of Rs. 840 ($19.5), mianserin Rs. 2010
($46.7), amoxapine Rs. 3835 ($89.1), amineptine Rs.
10,700 ($248.8), and the most expensive, tianeptine Rs.
21,000 ($488). The recently introduced antidepressant ser-
traline has an annual cost of Rs. 2740 ($63.7). Prophylaxis
for affective disorders with lithium therapy would have an
annual cost of Rs. 1200 ($27.9). Regarding antipsychotics
the annual direct costs of oral medications of chlorprom-
azine and haloperidol were same, Rs. 2000 ($46.5), long
acting oral penfluridol Rs. 500 ($11.6), and depot long act-
ing injectable fluphenazine decanoate, haloperidol de-
canoate, and flupenthixol Rs. 750 ($17.4), Rs. 1500 ($34.9)
and Rs. 2100 ($48.8), respectively. Newer atypical antipsy-
chotics risperidone, Rs. 4500 ($104.7) and clozapine Rs.
5500 ($127.9). Benzodiazepines have an annual cost of
$7.5 for diazepam, $3.5 for lorazepam and chlordiazep-
oxide, $2.8 for oxazepam, and $17.6 for alprazolam. Sleep
medications nitrazepam, flurazepam, and zopiclone have an
annual cost of $3.3, $8, and $18.8, respectively.
CONCLUSION: The annual direct costs are compara-
tively less than those in Western nations, but nevertheless
these produce a significant burden on the Indian families,
and are a common reason for poor compliance. Another
trend that can be noted above is that newer antidepres-
sants like amineptine and tianeptine, antipsychotics like
risperidone and clozapine, and hypnotics like zopiclone
are much more expensive than the older medications.
Thus, the annual direct costs of medications are only
likely to increase with time, enhancing the financial bur-
den in the treatment of the psychiatric disorders.
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OBJECTIVES: To profile utilization of antipsychotic
medications at baseline in a prospective study of the out-
comes of treatment for schizophrenia in large systems of
care, and to evaluate characteristics associated with the
receipt of antipsychotic medication and the type of medi-
cation prescribed.
METHODS: Data are obtained from the Schizophrenia
Care and Assessment Program, a prospective study of the
course and outcomes of treatment for schizophrenia in six
large systems of care in the United States. The analysis
sample consists of approximately 1100 patients. Antipsy-
chotic medication use at baseline in this sample is profiled.
The effect of patient characteristics and prior period (pre-
vious 6 months) service utilization and medication history
on receipt of antipsychotic medication therapy at baseline
and the type of medication prescribed is modeled using lo-
gistic regression.
RESULTS: The presentation will profile antipsychotic
utilization at baseline in this sample of patients receiving
care in large service systems, and characterize the distri-
bution of use of conventional, new generation, and depot
medication. Regression analysis will evaluate factors as-
sociated with the receipt of antipsychotic medication
therapy and type of medication prescribed. Predictors
will include: patient demographic status (age, gender,
race/ethnicity, education, marital status, income, health
insurance status), diagnosis (type of schizophrenia), psy-
chiatric history, and pre-period health services utilization
and medication history.
CONCLUSIONS: The introduction of new pharmaco-
logic treatments for schizophrenia and the development of
evidence-based standards of care has accelerated the need
for information on patterns of medication therapy and
outcomes in usual care settings. This presentation will
profile antipsychotic medication use and factors associ-
ated with current prescribing practices in a large sample
of patients with schizophrenia who receive care in large
service systems.
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With the growing elderly population, the number of
older patients with mental and behavioral disorders has
increased. Psychotropic drugs are an integral part of
treatment for these conditions.
OBJECTIVE: This study describes the psychotropic agent
prescribing for the elderly in clinic settings during 1996.
METHODS: Data were abstracted from the 1996 Na-
tional Ambulatory Medical Care Survey and the Na-
tional Hospital Ambulatory Medical Care Survey. All
visits of patients 65 years of age or older involving psy-
chotropic drugs were selected from the national surveys.
National visit estimates and visit rates were derived based
on the patient sampling weight to describe psychotropic
prescribing for the elderly in ambulatory clinics.
RESULTS: Psychotropic medications were prescribed in
an estimated 16.55 million ambulatory clinic visits for
